MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells

Conclusions Our results suggest that SAHA may be used as a single-drug treatment option for neuroblastomas with an amplified MYCN gene, and as an adjuvant treatment option for all neuroblastomas.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research